ZA200703751B - Ophthalmic oil-in-water type emulsion with stable positive zeta potential - Google Patents

Ophthalmic oil-in-water type emulsion with stable positive zeta potential

Info

Publication number
ZA200703751B
ZA200703751B ZA200703751A ZA200703751A ZA200703751B ZA 200703751 B ZA200703751 B ZA 200703751B ZA 200703751 A ZA200703751 A ZA 200703751A ZA 200703751 A ZA200703751 A ZA 200703751A ZA 200703751 B ZA200703751 B ZA 200703751B
Authority
ZA
South Africa
Prior art keywords
zeta potential
water type
type emulsion
positive zeta
stable positive
Prior art date
Application number
ZA200703751A
Other languages
English (en)
Inventor
Bague Severine
Philips Betty
Rabinovich-Guilatt Laura
Lambert Gregory
Garrigue Jean-Sebastien
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703751(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Publication of ZA200703751B publication Critical patent/ZA200703751B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA200703751A 2004-11-09 2005-10-10 Ophthalmic oil-in-water type emulsion with stable positive zeta potential ZA200703751B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292645A EP1655021B1 (en) 2004-11-09 2004-11-09 Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential

Publications (1)

Publication Number Publication Date
ZA200703751B true ZA200703751B (en) 2008-08-27

Family

ID=34931510

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703751A ZA200703751B (en) 2004-11-09 2005-10-10 Ophthalmic oil-in-water type emulsion with stable positive zeta potential

Country Status (14)

Country Link
US (5) US8298568B2 (xx)
EP (1) EP1655021B1 (xx)
JP (3) JP5587936B2 (xx)
CN (3) CN103356481B (xx)
AT (5) ATE412400T1 (xx)
DE (5) DE602004017477D1 (xx)
DK (1) DK1809237T3 (xx)
ES (4) ES2314354T3 (xx)
HK (2) HK1107938A1 (xx)
IL (3) IL181446A (xx)
MX (2) MX2007005545A (xx)
NZ (1) NZ554929A (xx)
PT (2) PT1809238E (xx)
ZA (1) ZA200703751B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8232320B2 (en) 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
JP2008535918A (ja) * 2005-04-11 2008-09-04 ナノバイオ コーポレーション 感染性の症状を処置するための四級アンモニウムハライド
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
EP1951200A2 (en) * 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
AU2014201978B2 (en) * 2006-07-28 2016-03-10 Santen Sas Compositions containing quaternary ammonium compounds
PL1891939T3 (pl) * 2006-07-28 2014-01-31 Santen Sas Kompozycje zawierające czwartorzędowe związki amonowe
EP2444829A1 (en) 2006-09-14 2012-04-25 Carl Zeiss SMT GmbH Optical element unit and method of supporting an optical element
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
JP5646331B2 (ja) * 2007-10-16 2014-12-24 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 新規眼科用組成物
US7834172B2 (en) * 2007-11-14 2010-11-16 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
WO2009063081A2 (en) * 2007-11-14 2009-05-22 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
EP2077104A1 (en) * 2008-01-02 2009-07-08 Novagali Pharma SA Micellar compositions with ophtalmic applications
EP2077105A1 (en) * 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmic Micellar Compositions with Enhanced Stability
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
BRPI0918244A2 (pt) * 2008-09-04 2015-12-15 Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd agente promotor do crescimento de pelos, e método para prevenir ou tratar uma doença associada com os cabelos.
EP2331128B1 (en) * 2008-09-05 2013-11-06 CEVA Santé Animale SA Composition comprising chitosan for ocular administration of vaccine(s) to avians
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
EP2396070A4 (en) 2009-02-12 2012-09-19 Incept Llc ACTIVE COMPOSITION WITH HYDROGEL PLUGS
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2228057A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Cationic oil-in-water emulsions containing prostaglandins and uses thereof
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CA2780925A1 (en) * 2009-11-09 2011-05-12 Allergan, Inc. Compositions for enhancing hair growth
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
AU2011278924B2 (en) * 2010-07-15 2015-06-18 Eyenovia, Inc. Ophthalmic drug delivery
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
CN103415292A (zh) 2011-01-26 2013-11-27 阿勒根公司 用于治疗眼科病症的雄性激素组合物
ES2666857T3 (es) 2011-07-18 2018-05-08 Mor-Research Applications Ltd. Un dispositivo para ajustar la presión intraocular
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
ES2791751T3 (es) * 2011-11-15 2020-11-05 Allergan Inc Suspensiones de forma 2 de ciclosporina A
JP6368244B2 (ja) 2011-11-15 2018-08-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ オートクレーブ可能なシクロスポリンａ２型の懸濁剤
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013125026A1 (ja) * 2012-02-24 2013-08-29 ファインバイオメディカル有限会社 潤滑性調整液
CA3050298A1 (en) * 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
EP2892564A4 (en) * 2012-09-06 2016-04-27 Univ Nanyang Tech HYALURONIC ACID MEDICINE DELIVERY SYSTEMS
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
CA2939952C (en) 2013-03-05 2022-03-22 Morgan V. Fedorchak Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
KR102285110B1 (ko) * 2013-03-13 2021-08-02 산텐 세이야꾸 가부시키가이샤 마이봄 기능부전의 치료제
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
RU2513597C1 (ru) * 2013-04-17 2014-04-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (xx) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015123272A1 (en) 2014-02-11 2015-08-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
EP3104841A4 (en) * 2014-02-14 2017-09-06 Jingjun Huang Compositions of nanoemulsion delivery systems
US20170087096A1 (en) * 2014-06-13 2017-03-30 Sanofi Nanocapsular formulation of active pharmaceutical ingredients
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016100972A2 (en) * 2014-12-19 2016-06-23 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
EP3253372B8 (en) * 2015-02-06 2022-06-22 Woodstock Sterile Solutions, Inc. Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
CN106176600A (zh) * 2015-05-07 2016-12-07 上海现代药物制剂工程研究中心有限公司 一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
JP7072517B2 (ja) 2016-02-29 2022-05-20 サン ファーマ グローバル エフゼットイー 局所用シクロスポリン含有製剤およびその使用
JP6906899B2 (ja) * 2016-03-30 2021-07-21 小林製薬株式会社 乳化組成物
JP6774508B2 (ja) 2016-05-03 2020-10-28 ニューマ・リスパイラトリー・インコーポレイテッド 流体を肺系に供給するための液滴送達装置、及びその使用方法
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
CN106782348A (zh) * 2017-01-04 2017-05-31 深圳市华星光电技术有限公司 一种led背光驱动电路及液晶显示器
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Anhydrous compositions of MTOR inhibitors and method of use
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
CN111278401B (zh) * 2017-05-30 2023-08-15 艾克思摩尔有限公司 递送抗生素大环内酯治疗干眼综合征的组合物和方法
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
WO2019071008A1 (en) 2017-10-04 2019-04-11 Pneuma Respiratory, Inc. ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE
EP4344719A2 (en) 2017-10-17 2024-04-03 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
US11253480B2 (en) 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
AU2019226051A1 (en) * 2018-02-26 2020-09-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110237233B (zh) * 2019-07-30 2021-01-15 沈阳兴齐眼药股份有限公司 一种含有环孢素的眼用药物组合物、其制备方法及用途
EP4069220A4 (en) * 2019-12-04 2024-04-24 Restore Vision Llc OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA
CN116437909A (zh) * 2020-06-10 2023-07-14 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
EP4359046A1 (en) 2021-06-22 2024-05-01 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
CN113577024B (zh) * 2021-08-20 2023-05-05 山西利普达医药科技有限公司 一种眼用组合物及其制备方法和应用
CN116407499A (zh) * 2021-12-29 2023-07-11 辅必成（上海）医药科技有限公司 一种他克莫司眼用乳剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
AU680813B2 (en) * 1992-08-28 1997-08-14 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) * 1993-04-08 2004-08-11 ライオン株式会社 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
ATE168553T1 (de) * 1993-06-25 1998-08-15 Alcon Cusi S A Neue verwendung von polymeren membranen zum ausgeben von pharmazeutischen lösungen, die quarternäre, als konserviermittel dienende ammoniumverbindungen enthalten und entsprechender dosierbehälter
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
RU2119351C1 (ru) * 1994-06-01 1998-09-27 Юхан Корпорейшн Иммуносупрессорная композиция, содержащая циклоспорин, и способ ее получения
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
EP0878197B1 (en) 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) * 1998-12-31 2002-09-26 Amitee Cosmetics, Inc. Stabilized ascorbic acid composition
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
WO2002085248A2 (en) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
ES2343512T3 (es) * 2001-11-01 2010-08-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procedimiento y composicion para el tratamiento del ojo seco.
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
PT1532981E (pt) 2002-08-23 2007-12-12 Santen Pharmaceutical Co Ltd Colírios estáveis contendo latanoprost como ingrediente activo
KR101182496B1 (ko) 2002-09-09 2012-09-12 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) * 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) * 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
JP4999304B2 (ja) * 2004-09-27 2012-08-15 ロート製薬株式会社 ヒアルロン酸又はその塩を含有する粘膜適用組成物
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
EP1929996B1 (en) * 2004-11-09 2011-02-16 Novagali Pharma S.A. Ophthalmic emulsions containing an immunosuppressive agent
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
JP2011521957A (ja) * 2008-05-28 2011-07-28 アルコン リサーチ， リミテッド 自己防腐エマルジョン
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2228057A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Cationic oil-in-water emulsions containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

Also Published As

Publication number Publication date
US8273362B2 (en) 2012-09-25
ATE412400T1 (de) 2008-11-15
US20070248645A1 (en) 2007-10-25
EP1655021A1 (en) 2006-05-10
ATE415942T1 (de) 2008-12-15
IL182897A0 (en) 2007-08-19
CN103356481A (zh) 2013-10-23
EP1655021B1 (en) 2008-10-29
HK1107938A1 (en) 2008-04-25
US8372434B2 (en) 2013-02-12
PT1809237E (pt) 2009-04-09
JP2012162549A (ja) 2012-08-30
JP2012149102A (ja) 2012-08-09
CN101056615B (zh) 2011-05-11
IL181446A0 (en) 2007-07-04
JP5587936B2 (ja) 2014-09-10
IL182897A (en) 2010-12-30
IL190497A (en) 2012-01-31
ATE498392T1 (de) 2011-03-15
JP5773941B2 (ja) 2015-09-02
CN101014317A (zh) 2007-08-08
CN101056615A (zh) 2007-10-17
PT1809238E (pt) 2009-02-09
US20090028955A1 (en) 2009-01-29
ES2320574T3 (es) 2009-05-25
DE602005010733D1 (de) 2008-12-11
DE602005026464D1 (de) 2011-03-31
DE602004017477D1 (de) 2008-12-11
ATE412401T1 (de) 2008-11-15
US20080268020A1 (en) 2008-10-30
CN103356481B (zh) 2017-11-28
ATE418964T1 (de) 2009-01-15
DE602005012136D1 (de) 2009-02-12
JP5894202B2 (ja) 2016-03-23
MX2007005545A (es) 2007-07-05
MX2007003045A (es) 2007-08-02
US20080107738A1 (en) 2008-05-08
ES2314354T3 (es) 2009-03-16
US20060100288A1 (en) 2006-05-11
US8298568B2 (en) 2012-10-30
NZ554929A (en) 2010-09-30
JP2014088450A (ja) 2014-05-15
DK1809237T3 (da) 2009-05-04
IL190497A0 (en) 2008-11-03
IL181446A (en) 2010-06-16
ES2319129T3 (es) 2009-05-04
ES2317319T3 (es) 2009-04-16
HK1112411A1 (en) 2008-09-05
US8298569B2 (en) 2012-10-30
DE602005011480D1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
ZA200703751B (en) Ophthalmic oil-in-water type emulsion with stable positive zeta potential
TWI366471B (en) Compositions and methods for localized therapy of the eye
EP1929996A3 (en) Ophthalmic emulsions containing an immunosuppressive agent
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
WO2002083097A3 (en) Drug delivery system for hydrophobic drugs
WO2004026231A3 (en) Formulation for lipophilic agents
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
IL174561A0 (en) Drug coating providing high drug loading and methods for providing the same
WO2006073950A3 (en) Nanoparticles for protein drug delivery
GR3031623T3 (en) Oil-in-water emulsions of positively charged particles.
WO2006113505A3 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
IL188774A0 (en) Compositions for delivery of drug combinations
MX2009001461A (es) Suministro por etapas multiples de agentes activos.
WO2008067164A3 (en) Solid pharmaceutical dosage formulations
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
SI1561460T1 (sl) Nanodelci za aplikacijo uäśinkovin, postopek za pripravo teh delcev in sestavek, ki jih vsebuje
WO2006050246A3 (en) Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy
BRPI0504082A (pt) emulsões refrescantes medicinais
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
WO2006003519A3 (en) Use of emulsions for intra: and periocular injection
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof